Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection

Stephen Pianko, Lawrence M. Blatt, John G. McHutchison, Stuart C. Gordon, Shanon Heaton, Zachary D. Goodman, Keyur Patel, Cherise M. Cortese, Elizabeth M. Brunt, Bruce R. Bacon

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


In patients with chronic hepatitis C, prior studies have suggested that increased hepatic iron concentration (HIC) is predictive of a poor response to interferon (IFN) monotherapy. The aim of this study was to assess the importance of HIC on the virologic response to therapy with IFN alone or when combined with ribavirin. Records of 91 patients were reviewed for inclusion in this study. Fifty-one received IFN alone, and 40 received IFN plus ribavirin. HIC and serum iron studies, alanine aminotransferase (ALT) values, hepatitis C virus (HCV) genotype, and HCV RNA were determined prior to therapy. Sustained response was defined as the absence of HCV RNA 6 months after the end of therapy. In the IFN monotherapy group, mean HIC was higher for nonresponders (803 + 89 μg/g, range 130-2808 μg/g) compared with sustained responders (241 + 54 μg/g, range 187-295 μg/g) (p < 0.01). In contrast, in the combination therapy group, the mean HIC was similar for both groups (533 + 86 μg/g, range 79-1338 μg/g in the nonresponders, and 662 + 95 μg/g, range 94-2031 μg/g, in the sustained responders). No difference between transferrin saturation and serum ferritin level was observed in sustained responder or nonresponder patients treated with IFN plus ribavirin. IFN monotherapy nonresponder patients tended to have a higher HIC. With IFN plus ribavirin, the sustained virologic response rate was not affected by the HIC.

Original languageEnglish
Pages (from-to)483-489
Number of pages7
JournalJournal of Interferon and Cytokine Research
Issue number4
StatePublished - 2002


Dive into the research topics of 'Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection'. Together they form a unique fingerprint.

Cite this